SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Order online now!

www.rockland.com
tech@rockland.com
+1 484.791.3823

Datasheet for 000-001-C14

Flagellin Control Protein

Overview

Description:	Flagellin Control Protein - 000-001-C14
Item No.:	000-001-C14
Size:	100 µg
Applications:	SDS-PAGE, WB, Biochemical Assay
Origin:	Borrelia burgdorferi
Expressed in:	E. coli

Product Details

Background:	Flagellin is a protein found in the hollow cylinder forming the filament in bacterial flagellum. Its structure is helical, which is important for its function. Studies comparing a flagellate Borrelia to flagellated indicate that the flagella have a role in the invasion of human tissue. The N- and C-termini of flagellin form the inner core of the flagellar filament, and the central portion of the protein makes up the outer surface. While the terminus of the protein is quite similar between all bacterial flagellins, the central portion is variable. The flagellin genes are highly conserved among the different Borrelia species. Mammals often have acquired immune responses (T-cell and antibody responses) to flagellated bacterium. Some bacteria are able to switch between multiple flagellin genes in order to evade this response. Borrelia burgdorferi, the spirochete that is associated with Lyme Disease, may use this tactic when challenging mammals with infection. Borrelia have double-stranded linear plasmids in addition to supercoiled circular plasmids, in low copy number. This suggests that initiation of DNA replication and partitioning are carefully controlled during the cell division cycle. It is believed that expression of the various proteins associated with the spirochete may be regulated by the changes in tick life cycle, changes in conditions during tick feeding (such as temperature, pH, and nutrients) and/or in coordination with the course of infection of the mammal host, i.e., changes in environment as the spirochete migrates from the tick's midgut to its salivary glands to the mammal host. B. burgdorferi can attach to (and also differentially express antigens in) diverse tissues within the vertebrate host and the tick vector, suggesting that physiological factors other than pH and temperature may play roles in modulating B. burgdorferi gene expression. Lyme disease proteins are ideal for researchers interested in immunology, neurology, rheumatology, coinfections, autoimmune, and neurodegenerative diseases.
Synonyms:	41 kDa antigen, Borrelia burgdorferi p41, fla, Flagellar filament 41 kDa core protein, Bacterial flagellin, control protein
Species of Origin:	Borrelia burgdorferi

Expressed in:	E. coli
Type:	Recombinant Protein

Target Details

Gene Name:	BBU94A_0149, fla
Purity/Specificity:	Flagellin is a fusion protein with an MBP tag and was expressed in E. coli. Analysis by SDS-PAGE resulted in a pattern consistent with purified Flagellin and was estimated to be greater than 90% pure.
Relevant Links:	• UniProtKB - P11089 • NCBI - WP_002661938.1 • GeneID - 7106737

Application Details

Tested Applications:	SDS-PAGE, WB
Suggested Applications:	Biochemical Assay (Based on references)
Application Note:	Flagellin is suitable as a control in immunological assays. Specific conditions for reactivity should be optimized by the end user. Expect a band at 76.3 kDa Flagellin-MBP, (33.9 kDa for Flagellin and 42.4 kDa for MBP) in size corresponding to Flagellin by Western blotting in the appropriate cell lysate or extract. Flagellin Protein was tested in SDS-page and western blot.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	User Optimized
WB:	User Optimized

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	1.0 mg/mL by modified Lowry assay
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store vial at -20 °C prior to opening. Aliquot contents and freeze at -20 °C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to immediate use.
Expiration:	Expiration date is six (6) months from date of receipt.

Images



Figure
Systems serology profiling with Borrelia-specific antigens reveals patient heterogeneity. The heatmap shows the Z-scored measurements for 12 features, across 16 antigens for both refractory and responsive patients, visualized with joint fluid measurements in the upper half of the heatmap and serum measurements in the lower half of the heatmap. Only antigens detected above background for at least 30% of samples were included for each measurement. Statistical significance was assessed using the Mann-Whitney nonparametric test, with p values then corrected for multiple hypothesis testing via Benjamini-Hochburg, *p < 0.05, **p < 0.01, ***p < 0.001, else not significant. CRASP1 (p/n 000-001-C18), CRASP2 (p/n 000-001-C19), DbpA (p/n 000-001-B98), DbpB (p/n 000-001-C16), Arp37 (p/n 000-001-C09), flagellin (p/n 000-001-C14), OspA (p/n 000-001-C13), OspB (p/n 000-001-C15), OspC (p/n 000-001-C11), OspE (p/n 000-001-C10), p27 (p/n 000-001-C30), p35 (p/n 000-001-C12), p39 (p/n 000-001-C17), VlsE (p/n 000-001-C33). Fig 1. PMID: 38303696.



Figure
Antigen-specific IgG2, IgA1, and ADCD partitioning between compartments differs significantly across disease phenotypes. (A) Fraction of samples with non-zero measurements for ADCD, IgG1, IgG2, IgG3, and IgA1 for refractory (dark blue) and responsive (green) patients in the serum (dashed line) and joint fluid (solid line) for each antigen. Significant differences in distribution of non-zero measurements between fluids as assessed by a Fisher's exact test are denoted as *p < 0.05, **p < 0.01, ***p < 0.001 for refractory (dark blue) and responsive (green) samples after correction for multiple hypothesis testing via Benjamini-Hochburg. (B) Ratio of fraction of serum samples with non-zero measurements to fraction of joint fluid samples with non-zero measurements for ADCD, IgG1, IgG2, IgG3, and IgA1 for refractory (dark blue) and responsive (green) patients for each antigen. Significant differences in distributions of ratios between phenotypes are assessed by a Mann-Whitney nonparametric test, then corrected for multiple hypothesis testing via Benjamini-Hochburg. CRASP1, CRASP2, DbpA, DbpB, Arp37, flagellin, OspA, OspB, OspC, OspE, p27, p35, p39, VlsE: Rockland antigens. Fig 6. PMID: 38303696.



SDS-PAGE
SDS PAGE Results of Flagellin Control Protein. Lane 1: Flagellin Control Protein Non-Reduced [10µg]. Lane 2: Opal Prestained Molecular Weight Marker (p/n MB-210-0500). Lane 3: Flagellin Control Protein Reduced [10µg]. 4-20% Gel, Coomassie stained.

References

- Bowman KA. et al. Borrelia-specific antibody profiles and complement deposition in joint fluid distinguish antibiotic-refractory from -responsive Lyme arthritis. *iScience.* (2024)

www.rockland.com
tech@rockland.com
+1 484.791.3823

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.